FDA warnings highlight risks associated with contaminated supplements

MXBBB has announced the recall of one lot of its Umary Acid Hyaluronic supplements after laboratory testing by the U.S. Food and Drug Administration (FDA) revealed contamination with two undeclared drugs—diclofenac and omeprazole. The recalled product, sold in 30-caplet bottles containing 850 mg of hyaluronic acid, has been distributed through Amazon, solovital.com, retail stores, and other online platforms.

The recall follows months of FDA warnings about the potential dangers posed by Umary products, with advisories issued in June, July, and September.

Contaminating Drugs Identified

The FDA’s tests confirmed the presence of two pharmaceuticals not disclosed on the product’s label:

• Diclofenac, a prescription pain reliever, is associated with risks such as gastrointestinal bleeding, cardiovascular issues, and kidney damage when used without medical oversight.
• Omeprazole, a proton pump inhibitor used to treat acid reflux, may mask symptoms of severe stomach conditions like ulcers or cancer and can interact negatively with other medications.

The agency has emphasized the significant health risks posed by these hidden ingredients, particularly for individuals with underlying conditions or those taking other medications.

Adverse Reactions Reported

Consumers who used the supplement have reported various adverse reactions, including stomach issues, heart problems, and skin conditions. Health experts warn that the presence of omeprazole could delay the diagnosis of serious gastrointestinal disorders by masking critical symptoms.

Product Unavailable on Major Platforms

Following the recall, the affected product has been removed from major platforms, including Amazon and solovital.com. Retailers have ceased selling the supplement, and distribution efforts for the affected lot have been halted.

Consumer Advisory

Consumers who purchased the recalled Umary Acid Hyaluronic supplements are urged to stop using them immediately. Any adverse reactions should be reported to the FDA through the MedWatch program. The agency continues to remind the public to exercise caution when purchasing dietary supplements, particularly from brands with prior safety advisories.

The FDA’s investigation highlights the ongoing challenges in ensuring the safety of dietary supplements and underscores the importance of regulatory scrutiny in protecting public health.